Form 4: Janux Therapeutics Director Sheila Gujrathi Granted Significant Equity Awards

Janux Therapeutics, Inc. Director Sheila Gujrathi was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock, aligning her interests with shareholders.

Summary

• Sheila Gujrathi, a Director of Janux Therapeutics, Inc. (JANX), reported changes in her beneficial ownership of company securities.
• On June 11, 2025, Ms. Gujrathi was granted 3,750 restricted stock units (RSUs) at a price of $0 per unit.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• These RSUs will vest on the earlier of June 11, 2026, or the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• Following this transaction, Ms. Gujrathi beneficially owns 118,889 shares of common stock.
• Additionally, on June 11, 2025, Ms. Gujrathi was granted stock options to acquire 11,667 shares of common stock with an exercise price of $25.46 per share.
• These stock options will vest in equal monthly installments over the 12 months following June 11, 2025, or will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• The stock options have an expiration date of June 10, 2035.
• Following this transaction, Ms. Gujrathi beneficially owns 11,667 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a director receiving equity compensation, which aligns their interests with shareholders and is a standard practice. It does not contain negative news or significant positive financial results for the company as a whole.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, as their compensation is tied to the company's future performance.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects.

Future Outlook

The document indicates future vesting events for both the restricted stock units and stock options, contingent on the reporting person's continuous service. The RSUs are set to vest by June 11, 2026, or the next annual meeting, while options will vest monthly over 12 months from June 11, 2025, or fully at the next annual meeting.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the biotechnology or pharmaceutical industry, where aligning executive and director incentives with long-term shareholder value through equity grants is common.

Related Party Transactions

• The reported transactions involve the grant of equity awards (restricted stock units and stock options) from Janux Therapeutics, Inc. to Sheila Gujrathi, a director of the company. This constitutes a related party transaction as it is between the company and an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: While not directly impacting all employees, such compensation structures for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• Vesting of 3,750 restricted stock units on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders.
• Monthly vesting of 11,667 stock options over 12 months following June 11, 2025, or full vesting on the date of the next annual meeting of stockholders.

Key Dates

Keywords

Janux Therapeutics, JANX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Beneficial Ownership, Director Compensation